Neola Medical EN
  • Lung Monitoring
  • The Technology
  • Our Studies
  • About Us
  • Career
  • Investors
    • To invest in Neola Medical
    • Risks and uncertainties
    • Stock information
    • Annual General Meeting (Swedish)
    • Corporate governance
    • Certified Adviser
    • Rights Issues (Swedish)
      • Riktad Emission 2023
      • Företrädesemission 2022
      • IPO 2020
        • Teckningsoptioner av serie TO1
    • Investor Relations
    • Investor letters
    • Presentations
    • Press Releases
    • Reports and Financial Calendar
  • News
    • Press Releases
    • Articles and posts
      • 2018 – 2024
      • 2025
Select Page

Analyzes

Here you can find analyzes performed on Neola Medical.

Analyst Group, January 2022: Continuous Lung Monitoring for Infants in need

Analyst Group, Augusti 2021: Har vind i seglen

Analyst Group, Maj 2021: Allt fler byggstenar faller på plats

 

 

About Neola Medical

Neola Medical AB (publ) aims to advance neonatal intensive care with Neola®, a medical device designed to enable continuous lung monitoring and real-time alerts of potentially life-threatening complications. The technology is based on a cutting-edge spectroscopic method that measures changes in lung volume and oxygen gas concentration. Neola® has the potential to support better care, shorten time spent in intensive care, and contribute to healthier lives for preterm born babies. Founded in 2016 and headquartered in Lund, Sweden, Neola Medical builds on Sweden’s legacy of medical technology innovation and contributions to global health care.

Sweden, HQ

Neola Medical AB
Ideon Gateway
Scheelevägen 27
223 63 Lund
info@neolamedical.com

U.S. Office

Neola Medical, Inc.
Nordic Innovation House
470 Ramona Street PMB
Palo Alto CA 94301-1707
info@neolamedical.com

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkPersonal Data Policy